Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 3 clients • 10 examiners • 8 art units • 0 of 10 (0%) have an AI response strategy ready • 19 patents granted in the last 365 days
DUANE MORRIS LLP - Quest Diagnostics is a patent law firm specializing in Biotechnology & Pharmaceuticals. The firm has a significant career history with 13323 applications, indicating a broad base of experience. It maintains a resolved allowance rate of 87.79 percent, which highlights its effectiveness in securing patent rights for its clients. This level of performance is established through its extensive work in the Biotechnology & Pharmaceuticals field. The firm's track record is well-represented by its application volume.
Currently, this specific practice group has 7 pending office actions. The firm averages 3.37 office actions per allowance, reflecting the typical level of engagement with patent examiners. The combination of 13323 career applications and an 87.79 percent allowance rate provides a clear indication of the firm's long-term success and reliability. Practitioners can use the 3.37 average to benchmark the firm's prosecution efficiency for Quest Diagnostics matters. These data points offer a clear perspective on the firm's operational model.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (20%) |
| §103 only | 6 (60%) |
| §112 only | 1 (10%) |
| Double-patenting + other | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FRITCHMAN, REBECCA M | 1 | 45.7% | +35.3% |
| SINGH, SATYENDRA K | 1 | 61.5% | +67.7% |
| SHELTON, SYNPHANE LA'SHAWN | 1 | 100.0% | +0.0% |
| WOOLWINE, SAMUEL C | 1 | 61.0% | +20.4% |
| CHEONG, CHEOM-GIL | 1 | 64.2% | +52.6% |
| BERTAGNA, ANGELA MARIE | 1 | 44.7% | +46.3% |
| MARTIN, PAUL C | 1 | 41.8% | +21.6% |
| IVICH, FERNANDO NMN | 1 | 48.7% | +69.8% |
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +48.0% |
| HAYES, JONATHAN EDWARD | 1 | 36.4% | +20.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18829111 | COMPOSITIONS AND METHODS FOR PURIFICATION AND DETECTION OF HDL AND APOAI | SHELTON, SYNPHANE LA'SHAWN | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17610044 | MULTIPLEX ASSAY FOR DETERMINING THE ß-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS | IVICH, FERNANDO NMN | 22d overdue |
| 17006360 | PATHOGENICITY SCORING SYSTEM FOR HUMAN CLINICAL GENETICS | HAYES, JONATHAN EDWARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17610044 | MULTIPLEX ASSAY FOR DETERMINING THE ß-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS | IVICH, FERNANDO NMN | 22d overdue |
| 17986339 | BORDETELLA DETECTION ASSAY | BERTAGNA, ANGELA MARIE | 20d |
| 19462819 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEX SAMPLES | FRITCHMAN, REBECCA M | — |
| 18884490 | MASS SPECTROMETRY METHOD FOR MEASURING THIAMINE IN BODY FLUID | SINGH, SATYENDRA K | — |
| 18794356 | METHODS FOR THE DIAGNOSIS OF BACTERIAL VAGINOSIS | WOOLWINE, SAMUEL C | — |
| 18270429 | COMPOUNDS, KITS, AND METHODS FOR BEAD-BASED DETECTION OF ANTI-MICROBE ANTIBODIES | CHEONG, CHEOM-GIL | — |
| 17588925 | Lp-PLA2 ASSAYS AND COMPOSITION WITH DETERGENT | MARTIN, PAUL C | — |
| 17201469 | METHOD FOR DETECTING CYSTIC FIBROSIS | SITTON, JEHANNE SOUAYA | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Quest Diagnostics | 7 |
| CLEVELAND HEARTLAB, INC. | 2 |
| Athena Diagnostics | 1 |
| Art Unit | Apps |
|---|---|
| 1681 | 2 |
| 1758 | 1 |
| 1652 | 1 |
| 1645 | 1 |
| 1653 | 1 |
| 1678 | 1 |
| 1682 | 1 |
| 1685 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19462819 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEX SAMPLES | Quest Diagnostics Investments Incorporated | FRITCHMAN, REBECCA M | 1758 | §103 | Final Rejection | — | Pending | Jan 28, 2026 |
| 18884490 | MASS SPECTROMETRY METHOD FOR MEASURING THIAMINE IN BODY FLUID | Quest Diagnostics Investments Incorporated | SINGH, SATYENDRA K | §103§112DP | Non-Final OA | — | Pending | Sep 13, 2024 | |
| 18829111 | COMPOSITIONS AND METHODS FOR PURIFICATION AND DETECTION OF HDL AND APOAI | Cleveland Heartlab, Inc. | SHELTON, SYNPHANE LA'SHAWN | 1652 | §103 | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18794356 | METHODS FOR THE DIAGNOSIS OF BACTERIAL VAGINOSIS | Quest Diagnostics Investments LLC | WOOLWINE, SAMUEL C | 1681 | §103 | Final Rejection | — | Pending | Aug 05, 2024 |
| 18270429 | COMPOUNDS, KITS, AND METHODS FOR BEAD-BASED DETECTION OF ANTI-MICROBE ANTIBODIES | Quest Diagnostics Investments LLC | CHEONG, CHEOM-GIL | 1645 | §103 | Final Rejection | — | Pending | Jun 29, 2023 |
| 17986339 | BORDETELLA DETECTION ASSAY | Quest Diagnostics Investments LLC | BERTAGNA, ANGELA MARIE | 1681 | §112 | Final Rejection | 20d | Pending | Nov 14, 2022 |
| 17588925 | Lp-PLA2 ASSAYS AND COMPOSITION WITH DETERGENT | Cleveland Heartlab, Inc. | MARTIN, PAUL C | 1653 | §103 | Non-Final OA | — | Pending | Jan 31, 2022 |
| 17610044 | MULTIPLEX ASSAY FOR DETERMINING THE ß-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS | Quest Diagnostics Investments LLC | IVICH, FERNANDO NMN | 1678 | §101§103 | Non-Final OA | 22d overdue | Pending | Nov 09, 2021 |
| 17201469 | METHOD FOR DETECTING CYSTIC FIBROSIS | Quest Diagnostics Investments LLC | SITTON, JEHANNE SOUAYA | 1682 | §103 | Final Rejection | — | Pending | Mar 15, 2021 |
| 17006360 | PATHOGENICITY SCORING SYSTEM FOR HUMAN CLINICAL GENETICS | Athena Diagnostics, Inc. | HAYES, JONATHAN EDWARD | 1685 | §101§112 | Non-Final OA | — | Pending | Aug 28, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial